An ultrasensitive PSA test using nanoparticle-based technology may be able to definitively predict whether the cancer is cured long term or if it will recur, new research from Northwestern University?s Feinberg School of Medicine and the University International Institute for Nanotechnology, Chicago shows.
A group of physician-scientists at Memorial Sloan-Kettering Cancer Center has released what it is calling the most comprehensive genomic analysis of prostate cancer to date.
Radical prostatectomy and other surgical patients who participate in longer (15- to 30-minute) informed consent discussions better understand the proposed operation, according to a recent study.
Rep. Tom Rooney (R?FL) has launched a resolution to denote July 17, 2010 as "National Bladder Cancer Awareness Day."
Use of testosterone gel in older men with limited mobility and high rates of chronic illness resulted in higher risk of negative cardiovascular events, according to results of a recent study.
The Centers for Medicare and Medicaid Services has launched a National Coverage Analysis (NCA) of sipuleucel-T (Provenge), a recently approved cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant prostate cancer. The agent is the first in a new therapeutic class known as autologous cellular immunotherapies.
Population screening with the PSA test in men ages 50 to 69 years cut prostate cancer mortality nearly in half during a 14-year follow-up, according to data from a Swedish study published July 1 in the online edition of Lancet Oncology.
FDA has approved cabazitaxel (Jevtana), a chemotherapeutic agent used in combination with prednisone for treatment of advanced, hormone-refractory prostate cancer following docetaxel (Taxotere)-based treatment.
A recent study concludes that statin drugs may lessen the risk for return of prostate cancer in individuals who have undergone radical prostatectomy.
A model predicting the time for stone passage using radiographic parameters was recently validated and now appears to be ready for clinical use.
When I talked to urologists at the recently concluded AUA annual meeting about Richard D. Williams, MD, they all described Dick Williams, the person, first: Unassuming. Dedicated. Soft-spoken. Genuine.
It is, in my opinion, truly amazing how far we have come concerning hypospadias repair.
The 105th AUA annual meeting provided important research advances on several fronts. Two themes emerged across a number of presentations: utilization of various diagnostic techniques and treatment modalities (both overuse and underuse); and interrelationships among various non-urologic medical conditions.
If we don't [lower costs and eliminate waste] soon, our patients, our practices, our families, the economy, and our nation will suffer.
A prospective, standardized system that has been used to report complications of several urologic procedures can also be utilized for reporting complications during percutaneous nephrolithotomy.
For most urologists, the potential for serious side effects from hormone therapy comes as no surprise.
The antibiotic of choice for simple urinary tract infections, trimethoprim-sulfamethoxazole, has a resistance rate of 23% to the bacteria commonly associated with UTIs.
Most urologists' professional conduct is impeccable, but there is an occasional physician whose attitude and behavior make life at work difficult for everyone.
Concerns about regulations and time have changed the way urologists work with drug and device reps.
The Patient Protection and Affordable Care Act of 2010 specifically states that anyone receiving Medicare payments is obligated to identify and refund overpayments within 60 days of recognition.
Urologists and other physicians who serve Medicare patients have been given another temporary reprieve from a scheduled reimbursment cut.
With more and more doctors making use of e-mail, it is important to learn proper etiquette when communicating with patients.
Investing in an ETF provides investors with the ability to invest in index-type portfolios that replicate the returns of many widely known indexes.
Urology Times writer Penny Allen has won a 2010 AUA Excellence in Urology Health Reporting Award.
The American Society of Clinical Oncology has issued a guideline for the use of serum markers in the diagnosis, treatment, and management of germ cell tumors in men, most commonly testicular cancer.
A significant reduction in imaging use is apparent when urologists evaluate radiologist recommendations and then direct follow-up imaging, according to a recent study.
A urine test that is under development appears to show significant specificity when used to detect prostate cancer, according to a multi-institution study from researchers in Colorado, Pennsylvania, New York, and Virginia presented at the AUA annual meeting in San Francisco.
Weiss Memorial Hospital, Chicago, has appointed Norm Smith, MD, to the position of chief of urology.
The FDA has approved GE Healthcare?s Cysview (hexaminolevulinate hydrochloride) for the detection of nonmuscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.